 Denali Therapeutics NASDAQ:DNLI was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Monday, Zacks.com reports. According to Zacks, Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimers disease, Parkinsons ... 